GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (NAS:XGN) » Definitions » Total Stockholders Equity

Exagen (Exagen) Total Stockholders Equity : $19.99 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Exagen Total Stockholders Equity?

Exagen's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $19.99 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Exagen's Book Value per Share for the quarter that ended in Mar. 2024 was $1.15. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Exagen's Debt-to-Equity for the quarter that ended in Mar. 2024 was 1.17.

Exagen Total Stockholders Equity Historical Data

The historical data trend for Exagen's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exagen Total Stockholders Equity Chart

Exagen Annual Data
Trend Dec13 Dec14 Dec15 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 55.66 41.84 84.94 42.46 22.69

Exagen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.94 31.90 27.50 22.69 19.99

Exagen  (NAS:XGN) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Exagen's Book Value per Share for the quarter that ended in Mar. 2024 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(19.991-0)/17.3179
=1.15

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Exagen's Debt-to-Equity for the quarter that ended in Mar. 2024 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(1.711 + 21.766) / 19.991
=1.17

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exagen Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Exagen's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Exagen (Exagen) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exagen Inc (NAS:XGN) » Definitions » Total Stockholders Equity
Comparable Companies
LMDX AKUMQ CNTG STIM CHEK MYNZ OCX TTOO TRIB DRIO TMO DHR SHSE:603259 IDXX IQV A XSWX:LONN MTD ICLR ILMN
Traded in Other Exchanges
E08A:Germany
Address
1261 Liberty Way, Vista, CA, USA, 92081
Website
https://www.exagen.com
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Executives
John Aballi director, officer: President and CEO C/O DECIPHER BIOSCIENCES, INC., 6925 LUSK BLVD, SUITE 200, SAN DIEGO CA 92121
Paul Kim director 4399 SANTA ANITA AVE, EL MONTE CA 91731
Tullis Growth Fund Ii, L.p. 10 percent owner 11770 US HWY 1, STE 503, PALM BEACH GARDENS FL 33408
Kamal Adawi officer: Chief Financial Officer C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92131
Mark Hazeltine officer: Chief Operating Officer C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Wendy S. Johnson director 800 E. LEIGH STREET, SUITE 209, RICHMOND VA 21219
Tullis James L L director, 10 percent owner 100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Ana Hooker director 441 CHARMANY DRIVE, MADISON WI 53719
Frank Stokes director C/O CASTLE BIOSCIENCES, 820 S. FRIENDSWOOD DRIVE, SUITE 201, FRIENDSWOOD TX 77546
Hunt Holdings Limited Partnership 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Nmsic Co-investment Fund, L.p. 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Debra Zack officer: Chief Medical Officer C/O EXAGEN, INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
H.i.g. Bio-exagen, L.p. 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081
Thierry Dervieux officer: Chief Scientific Officer C/O EXAGEN DIAGNOSTICS, INC., 1261 LIBERTY WAY, VISTA CA 92081
Nmsic Focused Llc 10 percent owner C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE C, VISTA CA 92081